New ALS pill enters human testing
NCT ID NCT07369076
Summary
This early-stage trial is testing an oral medication called NB-4746 in people with ALS (amyotrophic lateral sclerosis). The main goals are to check the drug's safety, see how the body processes it, and measure if it affects a blood marker of nerve damage. About 80 participants will take either the drug or a placebo for different periods, with some continuing for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.